Shareholders Equity: The sum of preferred and common equity items.
Dyne Therapeutics, Inc. (DYN) had Shareholders Equity of $972.13M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-111.95M |
|
-- |
|
-- |
|
$116.13M |
|
$-116.13M |
|
$4.17M |
|
$-111.95M |
|
$-111.95M |
|
$-111.95M |
|
$-111.95M |
|
$-111.95M |
|
$-111.95M |
|
$-116.13M |
|
$-116.00M |
|
128.44M |
|
128.44M |
|
$-0.69 |
|
$-0.69 |
|
| Balance Sheet Financials | |
$1.13B |
|
$24.03M |
|
$60.37M |
|
$1.19B |
|
$50.62M |
|
$148.92M |
|
$164.20M |
|
$214.83M |
|
$972.13M |
|
$972.13M |
|
|
Shareholders Equity |
$972.13M |
164.95M |
|
| Cash Flow Statement Financials | |
$-403.21M |
|
$-28.75M |
|
$890.31M |
|
$437.39M |
|
$895.74M |
|
$458.35M |
|
$45.85M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
22.25 |
|
-- |
|
-- |
|
0.13 |
|
0.15 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-405.13M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-11.52% |
|
-11.52% |
|
-9.43% |
|
-9.99% |
|
$5.89 |
|
$-3.15 |
|
$-3.14 |
|